Compare MFIC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MFIC | EVO |
|---|---|---|
| Founded | 2004 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4553 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 873.1M | 1.1B |
| IPO Year | N/A | N/A |
| Metric | MFIC | EVO |
|---|---|---|
| Price | $10.93 | $3.07 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $11.25 | $7.00 |
| AVG Volume (30 Days) | ★ 652.6K | 47.1K |
| Earning Date | 05-06-2026 | 04-08-2026 |
| Dividend Yield | ★ 10.84% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $1.37 |
| Revenue Next Year | N/A | $10.05 |
| P/E Ratio | $10.50 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.48 | $2.31 |
| 52 Week High | $13.51 | $4.42 |
| Indicator | MFIC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 43.77 | 56.03 |
| Support Level | $10.48 | $2.88 |
| Resistance Level | $11.81 | $3.75 |
| Average True Range (ATR) | 0.26 | 0.07 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 32.28 | 89.58 |
MidCap Financial Investment Corp is an externally managed, publicly traded, closed-end, diversified management investment company. The investment objective of the company is to generate current income and, to a lesser extent, long-term capital appreciation. It predominantly invests in directly originated and privately negotiated first lien senior secured loans to privately held U.S. middle-market companies, and in other types of securities including, first lien unitranche, second lien senior secured, unsecured, subordinated, and mezzanine loans, and equities in both private and public middle market companies.
Evotec SE is a life science company focused on developing pharmaceutical products through standalone services, integrated R&D programs, and strategic partnerships with pharmaceutical and biotechnology companies, academic institutions, and other partners. It operates across drug discovery, preclinical development, and manufacturing, with expertise in areas including oncology, central nervous system, cardiovascular-renal, immune and inflammatory, infectious, and other diseases. The Company generates revenue through fee-for-service and FTE-based services, milestones, and royalties, and equity ownership in biotechnology and academic projects. It operates through the Shared R&D and Discovery & Preclinical Development (D&PD) segments, with the majority of revenue generated from the USA.